Interní Med. 2009; 11(6): 298-300

Significance of combined hypolipidemic therapy for patients with metabolic syndrome

MUDr. Renáta Palmajová
NZZ - diabetologická a metabolická ambulancia, Bratislava, Podunajské Biskupice

Metabolic syndrome represents a complex of metabolic disorders of serious nature in which lipid disorders are among significant risk

factors for developing cardiovascular disease with high morbidity and mortality. Treatment of dyslipidemia with statins or fibrates is

among the most widely used therapies. Statin-fibrate combination therapy has been shown to not have an increased risk of adverse

effects and to be pharmacologically complementary. However, not even a positive, laboratory-based, therapeutic effect can eliminate

the risk of developing a serious cardiovascular disease completely. Diabetic/metabolic dyslipidemia is more susceptible to combination

therapy than other types of lipid metabolism disorders. When indicated and administered properly, statin-fibrate combination therapy

currently represents a significant treatment option of dyslipidemia reducing a high cardiovascular risk.

Keywords: dyslipidemia, metabolic syndrome, cardiovascular risk, fibrates, statin-fibrate combination therapy.

Published: July 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Palmajová R. Significance of combined hypolipidemic therapy for patients with metabolic syndrome. Interní Med. 2009;11(6):298-300.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article


    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.